These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1748145)

  • 1. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
    Hermann LS; Karlsson JE; Sjöstrand A
    Eur J Clin Pharmacol; 1991; 41(3):263-5. PubMed ID: 1748145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).
    Elkeles RS
    Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes.
    Rains SG; Wilson GA; Richmond W; Elkeles RS
    Diabet Med; 1988 Oct; 5(7):653-8. PubMed ID: 2975549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus.
    Hermann LS; Kjellström T; Nilsson-Ehle P
    Diabete Metab; 1991 May; 17(1 Pt 2):174-9. PubMed ID: 1936472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.
    Sundaresan P; Lykos D; Daher A; Diamond T; Morris R; Howes LG
    Diabetes Care; 1997 May; 20(5):692-7. PubMed ID: 9135928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients.
    Raptis AE; Tountas NB; Yalouris AG; Halvatsiotis PG; Raptis SA
    Horm Metab Res; 1996 Feb; 28(2):89-94. PubMed ID: 8867905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
    Clauson P; Karlander S; Steen L; Efendic S
    Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.
    Chan JC; Tomlinson B; Critchley JA; Cockram CS; Walden RJ
    Diabetes Care; 1993 Jul; 16(7):1035-8. PubMed ID: 8359098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus.
    Groop L; Widén E; Franssila-Kallunki A; Ekstrand A; Saloranta C; Schalin C; Eriksson J
    Diabetologia; 1989 Aug; 32(8):599-605. PubMed ID: 2506091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Technol Ther; 2004 Feb; 6(1):1-8. PubMed ID: 15000763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of combined therapies in treatment of secondary failure to glyburide.
    Trischitta V; Italia S; Mazzarino S; Buscema M; Rabuazzo AM; Sangiorgio L; Squatrito S; Vigneri R
    Diabetes Care; 1992 Apr; 15(4):539-42. PubMed ID: 1499473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus.
    Waysbort J; Regitz G; Chaimowitz D; Tuval M; Nakash I; Brunner D
    Clin Ther; 1988; 10(4):358-71. PubMed ID: 2978874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
    Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
    Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
    Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
    Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment.
    Peacock I; Watts R; Selby C; Tattersall RB
    Diabetes Res; 1987 Oct; 6(2):57-9. PubMed ID: 3123115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.
    Hermann LS; Bitzén PO; Kjellström T; Lindgärde F; Scherstén B
    Diabete Metab; 1991 May; 17(1 Pt 2):201-8. PubMed ID: 1936477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.